摘要
目的研究吉西他滨联合奈达铂对晚期三阴乳腺癌的治疗效果。方法收集2010年5月~2012年5月于佛山市第一人民医院就诊的晚期TNBC患者70例,将患者按绝经前后、转移部位以及首发还是复发来进行分组,采用Ridit分析患者的治疗效果,比较患者的疗效差异是否具有统计学意义。采用Kaplan-Meier建立无进展生存期曲线,利用Log-rank检验比较疗效具有统计学意义的患者的无进展生存期是否存在差异。结果比较患者的疗效差异,发现首发组和复发组患者的疗效差异具有统计学意义,置信区间没有存在重合部分。整体比较首发组和复发组患者的无进展生存期差异,发现复发者患者的无进展生存期较首发组短,P=0.049,差异具有统计学意义。结论吉西他滨联合奈达铂对晚期三阴乳腺癌对首发组患者治疗效果明显。
Objective To study the therapeutic effect of the gemcitabine combined with nedaplatin on triple-negativebreast cancer（TNBC） cases at advanced stage. Methods Seventy TNBC patients at advanced stage in Foshan Municipal FIrstPeople’s Hospital were selected from May 2010 to May 2012 and divided into several groups based on pre- and post-menopausal, metastases and initiating lesion or recurrence.The therapeutic effecte were statistically analyzed assistant withRidit.. Progression-free survival（PFS）was established by using Kaplan-Meier. Log-rank was used to test differences of efficacyof progression-free survival of patients. Results The differences of efficcies in cases of initiating group and in the recurrentgroup were statistically significant withour overlapping in confidence intervals. When holistically comparing progression-freesurvivals of cases in initiating groups and the recurrent groups, progression-free survival of cases in initiating group was shorterthan that of the recurrent group showing statistically significant difference（P=0.049）. Conclusion The therapeutic effect ofnedaplatin combined with gemcitabine is markedly effective on initiated TNBC cases at advanced stage.
出处
《中国热带医学》
CAS
2015年第4期463-465,共3页
China Tropical Medicine
关键词
吉西他滨
奈达铂
三阴乳腺癌
Gemcitabine
Nedaplatin
Triple-negative breast cancer（TNBC）
